Bullish indicating open at $55-$60, IPO prices at $37
Jonathan Young, the Chief Operating Officer of Akero Therapeutics (NASDAQ:AKRO), recently executed significant stock sales totaling approximately $2.24 million. The transactions, which took place on March 4, 2025, involved the sale of 50,000 shares of common stock at prices ranging from $44.168 to $45.071 per share. The sale comes as the stock has shown remarkable strength, gaining over 71% in the past six months according to InvestingPro data.
Following these sales, Young retains direct ownership of 201,147 shares. The transactions were conducted under a pre-established Rule 10b5-1 trading plan, which allows company insiders to set up a predetermined schedule for selling stocks. Additionally, Young holds indirect ownership of 60,000 shares through irrevocable trusts for his children, which he disclaims beneficial ownership of. With a market capitalization of $3.6 billion and analyst price targets ranging from $60 to $109, InvestingPro analysis indicates the stock is currently fairly valued. InvestingPro subscribers have access to 10 additional key insights about AKRO’s financial health and market position.
In other recent news, Akero Therapeutics has seen several analysts raise their price targets for the company’s stock, reflecting positive developments in its treatment for non-alcoholic steatohepatitis (NASH). Citi analysts increased their price target to $80, highlighting promising 96-week SYMMETRY data for efruxifermin (EFX) in patients with compensated cirrhosis caused by metabolic-associated steatohepatitis. Canaccord Genuity also raised its price target to $73 following positive trial results, expressing optimism about the significant improvement in fibrosis for patients. Jefferies analyst Michael Yee adjusted the price target to $75, citing strong Phase IIB trial results and the company’s potential in the NASH market. H.C. Wainwright updated its price target to $72, basing the valuation on a risk-adjusted net present value model for EFX. The firm’s analysis projects global peak revenues of $4.5 billion by 2037. Analysts have maintained a Buy rating across the board, indicating a positive outlook for Akero Therapeutics. The raised price targets reflect confidence in Akero’s potential market performance and the significance of its recent clinical data.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.